¿Dónde puedo obtener más información?
Su farmacéutico le puede dar más información acerca Corvo.
More common side effects
The more common side effects that can occur with Corvo include:
If these effects are mild, they may go away within a few days or a couple of weeks. If they’re more severe or don’t go away, talk to your doctor or pharmacist.
What Other Drugs Interact with Corvo?
If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first. Severe Interactions of Corvo include:
Corvo has serious interactions with at least 38 different drugs.
Corvo has moderate interactions with at least 110 different drugs.
Corvo has mild interactions with at least 31 different drugs.
This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist. Check with your physician if you have health questions or concerns.
Administration of VASOTEC to patients with hypertension of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients (see WARNINGS).
In most patients studied, after oral administration of a single dose of Corvo, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours.
At recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval (see DOSAGE AND ADMINISTRATION).
In some patients achievement of optimal blood pressure reduction may require several weeks of therapy.
The antihypertensive effects of VASOTEC have continued during long-term therapy. Abrupt withdrawal of VASOTEC has not been associated with a rapid increase in blood pressure.
In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of VASOTEC, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.
When given together with thiazide-type diuretics, the blood pressure lowering effects of VASOTEC are approximately additive.
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC (see DRUG INTERACTIONS).
Dosage Adjustment In Hypertensive Patients With Renal Impairment
The usual dose of Corvo is recommended for patients with a creatinine clearance more than 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance less than or equal to 30 mL/min (serum creatinine more than or equal to 3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.
7. Pregnancy and breastfeeding
Corvo is not normally recommended in pregnancy. However, your doctor may prescribe it if they think the benefits of the medicine outweigh the risks.
If you're trying to get pregnant or you're already pregnant, talk to your doctor about the benefits and possible harms of taking Corvo. These will depend on how many weeks pregnant you are and the reason you need to take it. There may be other treatments that are safer for you.
Corvo belongs to a class of medicines called angiotensin-converting enzyme (ACE) inhibitors. You may have been prescribed it to reduce high blood pressure (hypertension), or to prevent (or treat) heart failure. Heart failure is a condition where your heart does not work as well as it should.
¿Qué es Corvo?
Corvo es un inhibidor ECA. ECA se traduce a enzima convertidora de la angiotensina.
Corvo se usa en el tratamiento de la presión arterial elevada (hipertensión) en adultos y niños que tienen al menos 1 mes de edad.
Corvo también se usa para tratar el fallo cardíaco congestivo en los adultos.
Corvo se usa también para tratar un trastorno de los ventrículos (cámaras inferiores del corazón que permiten que la sangre salga del corazón). Este trastorno puede disminuir la capacidad del corazón de bombear sangre al cuerpo.
Corvo puede también usarse para fines no mencionados en esta guía del medicamento.
Q: About two weeks ago, while undergoing tests for allergies, I had an allergic reaction; swelling in my lips. I usually take Corvo 20 mg. It didn't seem to work to help lower my blood pressure, which rose to 183/121. Since then I've been careful to avoid anything with any type of nuts since the reaction was caused by almonds. However, yesterday, under my lower lip, I noticed a funny feeling and I eventually looked in the mirror. I saw redness and one small spot of swelling on the skin. I was baffled as to what could have caused it. I later remember it hadn't been long since I'd taken a dose of Corvo. Could this be angioedema? I have never had problems like this with Corvo and I've been taking it for at least five years. I do feel I have plateaued on it. I've been taking the maximum dose for more than a year and it doesn't seem to have the same effects as before. I can only take ACE inhibitors and ARBs to lower my blood pressure because of other medical conditions, including CHF. Should I switch to another ACE inhibitor? My blood pressure is around 140/90 when I take Corvo only, and I was supposed to have a second medication, but which one should I take? I've had trouble with some of the others including clonidine, nifedipine, Norvasc, metoprolol and propanolol, and they all had to be stopped.
A: Angioedema is an uncommon side effect associated with Corvo and usually occurs in the first month of treatment. Although it is possible to experience this condition later during treatment, it is more common in African American patients, women, and people who have a history of drug or seasonal allergies. The exact prevalence and incidence of ARB-induced angioedema are not known, but it is thought to be significantly lower than the ACE inhibitors. For patients who cannot take any other alternatives, ARBs seem to be the way to go for people who have had this issue with ACE inhibitors, although careful monitoring is recommended for the physician. There are no clear cut ways to distinguish which medication would be best in this case for your condition, but it has been shown that losartan (Cozaar) seems to show the most cases with angioedema, if it happens at all, with the ARBs. Lori Poulin, PharmD
¿Qué debo evitar mientras tomo Corvo?
Beber alcohol puede bajar mucho más su presión arterial y puede aumentar ciertos efectos secundarios de Corvo.
No use sustitutos de la sal o suplementos de potasio mientras esté tomando Corvo, salvo que su médico le indique hacerlo.
Evite levantarse muy rápido de la posición de sentado o acostado, ya que puede sentirse mareado. Levántese despacio y estabilícese para evitar que se caiga.
Potassium-sparing diuretics, potassium supplements, and potassium-containing salt substitutes
These medications increase your risk of high potassium levels in your blood when taken with Corvo. Examples of these drugs include:
Before taking Corvo,
- tell your doctor and pharmacist if you are allergic to Corvo; other ACE inhibitors such as benazepril (Lotensin, in Lotrel), captopril (Capoten), fosinopril (Monopril), lisinopril (in Prinzide, in Zestoretic), moexipril (Univasc, in Uniretic), perindopril (Aceon), quinapril (Accupril, in Accuretic, in Quinaretic), ramipril (Altace), and trandolapril (Mavik, in Tarka); any other medications; or any ingredients in Corvo tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor or pharmacist if you are taking valsartan and sacubitril (Entresto) or if you have stopped taking it within the last 36 hours. Your doctor will probably tell you not to take Corvo, if you are also taking valsartan and sacubitril. Also, tell your doctor if you have diabetes and you are taking aliskiren (Tekturna, in Amturnide, in Tekamlo, in Tekturna HCT). Your doctor will probably tell you not to take Corvo if you have diabetes and you are also taking aliskiren.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking. Be sure to mention any of the following: aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin (Indocin, Tivorbex); diuretics ('water pills'); lithium (Lithobid); and potassium supplements. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had heart or kidney disease; lupus; scleroderma (a condition in which extra tissue grows on the skin and some organs); diabetes; or angioedema (a condition that causes difficulty swallowing or breathing and painful swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs).
- tell your doctor if you are breastfeeding.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking Corvo.
- you should know that diarrhea, vomiting, not drinking enough fluids, and sweating a lot can cause a drop in blood pressure, which may cause lightheadedness and fainting.
Corvo may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
In a multicenter, placebo-controlled clinical trial, 2,569 patients with all degrees of symptomatic heart failure and ejection fraction ≤ 35 percent were randomized to placebo or Corvo and followed for up to 55 months (SOLVD-Treatment). Use of Corvo was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for heart failure. Diseases that excluded patients from enrollment in the study included severe stable angina (>2 attacks/day), hemodynamically significant valvular or outflow tract obstruction, renal failure (creatinine >2.5 mg/dL), cerebrovascular disease (e.g., significant carotid artery disease), advanced pulmonary disease, malignancies, active myocarditis and constrictive pericarditis. The mortality benefit associated with Corvo does not appear to depend upon digitalis being present.
A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction ≤ 35% and no history of symptomatic heart failure, were randomized to placebo (n=2117) or Corvo (n=2111) and followed for up to 5 years. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Corvo-treated subjects had 32% fewer first hospitalizations for heart failure, and 32% fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving Corvo developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the Corvo treatment group (for Corvo vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect.
The SOLVD-Prevention trial was not designed to determine whether treatment of asymptomatic patients with low ejection fraction would be superior, with respect to preventing hospitalization, to closer follow-up and use of Corvo at the earliest sign of heart failure. However, under the conditions of follow-up in the SOLVD-Prevention trial (every 4 months at the study clinic; personal physician as needed), 68% of patients on placebo who were hospitalized for heart failure had no prior symptoms recorded which would have signaled initiation of treatment.
The SOLVD-Prevention trial was also not designed to show whether Corvo modified the progression of underlying heart disease.
In another multicenter, placebo-controlled trial (CONSENSUS) limited to patients with NYHA Class IV congestive heart failure and radiographic evidence of cardiomegaly, use of Corvo was associated with improved survival. The results are shown in the following table.
In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both.
COMMON BRAND(S): Vasotec
GENERIC NAME(S): Corvo Maleate
This drug can cause serious (possibly fatal) harm to an unborn baby if used during pregnancy. Therefore, it is important to prevent pregnancy while taking this medication. Consult your doctor for more details and to discuss the use of reliable forms of birth control while taking this medication. If you are planning pregnancy, become pregnant, or think you may be pregnant, contact your doctor right away.
Corvo is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to help prevent people with a certain heart problem (left ventricular dysfunction) from developing heart failure.
Corvo belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.